SlideShare a Scribd company logo
1 of 2
Megan Handley
PharmD Candidate Class of 2015
Drug Information Question
Polymyxin B sulfate stability and compatibility with bacitracin for
injection
Polymyxin B for injection Package Insert (Sagent)
 “Polymyxin B sulfate solutions for parenteral use should be stored under refrigeration and any unused
portion should be discarded within 72 hours.”
 Dosage and Administration
o Parenteral:
 Dissolve 500,000 polymyxin B units in 300-500 mL of 5% Dextrose Injection for
continuous intravenous drip
o Intramuscular:
 Dissolve 500,000 polymyxin B units in 2 mL sterile water for injection or 0.9% sodium
chloride or procaine hydrochloride injection 1%
o Intrathecal
 Dissolve 500,000 polymyxin B units in 10 mL 0.9% sodiumchloride injection for 50,000
units per mL dosage
 Storage Recommendations
o After reconstitution, product must be stored under refrigeration, between 2º and 8ºC (36º and
46º F) and any unused portion should be discarded after 72 hours.
Stability of polymyxin B sulfate diluted in 0.9% sodium chloride injection and
stored at 4 or 25º C (He et al.)
 The study analyzed the stability of polymyxin B in infusion bags containing 0.9% sodium chloride at room
temperature and underrefrigeration
 They found that on average, the samples retained over 90% of their initial concentration for up to two days
at both storage temperatures.
 All samples retained over 90% of their initial concentration at 24 hours
 The decomposition kinetics of polymyxin B in infusion bags containing 0.9% sodium chloride injection
exhibited pseudo-first-order kinetics
o Rate constants of0.024-0.075 day-1 at 25ºC (loss of 2.4-7.5% concentration daily)
o Rate constants of0.022-0.043 day-1 at 4ºC (loss of 2.2-4.3% concentration daily)
 Polymyxin B was stable for at least 1 day when stored at 4 or 25ºC in infusion bags containing 0.9%
sodium chloride injection.
o Stability did not significantly differ between the two temperatures.
 Table 1 and Table 2 (attached) in the study break down the various manufacturers and lot numbers and
report the percentage of the original concentration of polymyxin b sulfate that remains each day. Results
are reported for both 4 and 25ºC.
 Based upon this study, I would keep all reconstituted polymyxinB in the refrigerator to lengthen its
stability.I also would discard the reconstituted product 48 hours after reconstitution. It would also be
good practice to make sure all employees note the day and exact time the product was reconstituted so it
can be discarded appropriately.
MICROMEDEX IV Compatibility Analysis
 Solutions reported to be compatible with polymyxin B include Dextrose 5%, Normal Saline (sodium
chloride 0.9%), and invert sugar7.5% with electrolytes.
 The compatibility detail for polymyxin B sulfate (0.0564-0.078 mg/mL) and normal saline (sodium
chloride 0.9%), cited the He et al. as their source for the reported stability of polymyxin B in sodium
chloride solution.
 The information specifies: All samples retained over 90% of their original concentration at 24 hours.
Within 48 hours,the concentrations in some samples exhibited greater than 10% loss in concentration,with
one sample having 17% lost.
 Bacitracin is not on the Micromedex list of compatible medications for IV treatment with polymyxin B.
Dactinomycin, daptomycin, octreotide, and cyclosporine are alternative cyclic peptides that are compatible
with polymyxin B sulfate for intravenous therapy.
Summary
Overall, there is very limited research thus far regarding the stability of polymyxin B sulfate in normal
saline solution. The package insert mentioned above does mention that polymyxin B can be reconstituted with
normal saline; however the storage recommendations do not specify a certain time period for each diluent. They
simply apply a 72 hourlimit on all reconstituted solutions ofpolymyxin B, which is the known time for polymyxin
B to lose stability in 5% dextrose.
He et al. conducted a study determining how much time must elapse for a solution of polymyxin B sulfate
in sodiumchloride injection to reach a concentration of less than 90% of its original strength.Since this study was
specific to normal saline as a diluent, the results may in turn be more specific than those mentioned in the package
insert. They determined polymyxin B sulfate was stable after reconstitution for at least 1 day when stored at either 4
or 25ºC (stability being defined as greater than 90% of the original concentration of polymyxin B.) Most solutions
maintained greater than 90% of their concentration after 48 hours,with the exception of some samples. More
samples of polymyxin B in normal saline bags maintained a stable concentration after 48 days if they were
refrigerated; however, the difference between the two groups was not statistically significant.

More Related Content

What's hot

AAPS 2016 solution poster
AAPS 2016 solution posterAAPS 2016 solution poster
AAPS 2016 solution poster
Haley Porter
 
CRS 2015 46inH x 18.5in W_Real Size 92inH by 37 in W_BH_MG_Final Reviewed
CRS 2015 46inH x 18.5in W_Real Size 92inH by 37 in W_BH_MG_Final ReviewedCRS 2015 46inH x 18.5in W_Real Size 92inH by 37 in W_BH_MG_Final Reviewed
CRS 2015 46inH x 18.5in W_Real Size 92inH by 37 in W_BH_MG_Final Reviewed
Brent Hilker
 
Simplification of Fed-Batch Processes Using Modified Amino Acids
Simplification of Fed-Batch Processes Using Modified Amino AcidsSimplification of Fed-Batch Processes Using Modified Amino Acids
Simplification of Fed-Batch Processes Using Modified Amino Acids
Merck Life Sciences
 

What's hot (20)

Protein Formulation Development
Protein Formulation DevelopmentProtein Formulation Development
Protein Formulation Development
 
Antimicrobial Effectiveness test
Antimicrobial Effectiveness testAntimicrobial Effectiveness test
Antimicrobial Effectiveness test
 
RESEARCH ARTICLE ON INCLUSION COMPLEX WITH SBE-B-CD
RESEARCH ARTICLE ON INCLUSION COMPLEX WITH SBE-B-CD RESEARCH ARTICLE ON INCLUSION COMPLEX WITH SBE-B-CD
RESEARCH ARTICLE ON INCLUSION COMPLEX WITH SBE-B-CD
 
MCQs for GPAT with answers
MCQs for GPAT with answersMCQs for GPAT with answers
MCQs for GPAT with answers
 
Dense Phase CO2 Preservation Technique
Dense Phase CO2 Preservation TechniqueDense Phase CO2 Preservation Technique
Dense Phase CO2 Preservation Technique
 
AAPS 2016 solution poster
AAPS 2016 solution posterAAPS 2016 solution poster
AAPS 2016 solution poster
 
Parenteral production
Parenteral productionParenteral production
Parenteral production
 
CRS 2015 46inH x 18.5in W_Real Size 92inH by 37 in W_BH_MG_Final Reviewed
CRS 2015 46inH x 18.5in W_Real Size 92inH by 37 in W_BH_MG_Final ReviewedCRS 2015 46inH x 18.5in W_Real Size 92inH by 37 in W_BH_MG_Final Reviewed
CRS 2015 46inH x 18.5in W_Real Size 92inH by 37 in W_BH_MG_Final Reviewed
 
Recovery of 4-Aminophenol from Aqueous Solution Using Different techniques
Recovery of 4-Aminophenol from Aqueous Solution Using Different techniques  Recovery of 4-Aminophenol from Aqueous Solution Using Different techniques
Recovery of 4-Aminophenol from Aqueous Solution Using Different techniques
 
Dense phase carbon dioxide core- Nonthermal technology for food processing
Dense phase carbon dioxide core- Nonthermal technology for food processingDense phase carbon dioxide core- Nonthermal technology for food processing
Dense phase carbon dioxide core- Nonthermal technology for food processing
 
Importance of Understanding the Physical State of Excipients in a Freeze Drie...
Importance of Understanding the Physical State of Excipients in a Freeze Drie...Importance of Understanding the Physical State of Excipients in a Freeze Drie...
Importance of Understanding the Physical State of Excipients in a Freeze Drie...
 
Chapter 4 drug cosmetic stability
Chapter 4   drug cosmetic stabilityChapter 4   drug cosmetic stability
Chapter 4 drug cosmetic stability
 
Aquametry ;
Aquametry ;Aquametry ;
Aquametry ;
 
Formulation possibilities of weak bases
Formulation possibilities of weak basesFormulation possibilities of weak bases
Formulation possibilities of weak bases
 
Simplification of Fed-Batch Processes Using Modified Amino Acids
Simplification of Fed-Batch Processes Using Modified Amino AcidsSimplification of Fed-Batch Processes Using Modified Amino Acids
Simplification of Fed-Batch Processes Using Modified Amino Acids
 
Seminar on solid state stability and shelf life by ranjeet singh
Seminar on solid state stability and shelf life by ranjeet singhSeminar on solid state stability and shelf life by ranjeet singh
Seminar on solid state stability and shelf life by ranjeet singh
 
TDS of high acyl gellan gum
TDS of high acyl gellan gumTDS of high acyl gellan gum
TDS of high acyl gellan gum
 
Solubility Enhancement, Stability and Scalability of Mesoporous Silica Formul...
Solubility Enhancement, Stability and Scalability of Mesoporous Silica Formul...Solubility Enhancement, Stability and Scalability of Mesoporous Silica Formul...
Solubility Enhancement, Stability and Scalability of Mesoporous Silica Formul...
 
Methods for standardization of antibiotics
Methods for standardization of antibiotics Methods for standardization of antibiotics
Methods for standardization of antibiotics
 
The Essentials of USP chapter 51 antimicrobial effectiveness testing
The Essentials of USP chapter 51 antimicrobial effectiveness testingThe Essentials of USP chapter 51 antimicrobial effectiveness testing
The Essentials of USP chapter 51 antimicrobial effectiveness testing
 

Viewers also liked

Walking In The Dark Final Version March 2015
Walking In The Dark Final Version March 2015Walking In The Dark Final Version March 2015
Walking In The Dark Final Version March 2015
Bria Barrows
 
ASEE-GSW_2015_submission_75
ASEE-GSW_2015_submission_75ASEE-GSW_2015_submission_75
ASEE-GSW_2015_submission_75
Sam Yang
 
scopp_chris_resume
scopp_chris_resumescopp_chris_resume
scopp_chris_resume
Chris Scopp
 
Invoice 111 p-5515-002_1_7811490091
Invoice 111 p-5515-002_1_7811490091Invoice 111 p-5515-002_1_7811490091
Invoice 111 p-5515-002_1_7811490091
iRewriter
 

Viewers also liked (10)

Synergy CRO capabilities as of 4 Aug 2016
Synergy CRO capabilities as of 4 Aug 2016Synergy CRO capabilities as of 4 Aug 2016
Synergy CRO capabilities as of 4 Aug 2016
 
Walking In The Dark Final Version March 2015
Walking In The Dark Final Version March 2015Walking In The Dark Final Version March 2015
Walking In The Dark Final Version March 2015
 
ASEE-GSW_2015_submission_75
ASEE-GSW_2015_submission_75ASEE-GSW_2015_submission_75
ASEE-GSW_2015_submission_75
 
Argentinos con teleSUR
Argentinos con teleSURArgentinos con teleSUR
Argentinos con teleSUR
 
scopp_chris_resume
scopp_chris_resumescopp_chris_resume
scopp_chris_resume
 
Invoice 111 p-5515-002_1_7811490091
Invoice 111 p-5515-002_1_7811490091Invoice 111 p-5515-002_1_7811490091
Invoice 111 p-5515-002_1_7811490091
 
опис досвіду
опис досвідуопис досвіду
опис досвіду
 
Coca Cola - IHRM
Coca  Cola - IHRMCoca  Cola - IHRM
Coca Cola - IHRM
 
Definicion criterios actuación estratégica para el desarrollo territorial Fas...
Definicion criterios actuación estratégica para el desarrollo territorial Fas...Definicion criterios actuación estratégica para el desarrollo territorial Fas...
Definicion criterios actuación estratégica para el desarrollo territorial Fas...
 
shady samy cv
shady samy cvshady samy cv
shady samy cv
 

Similar to Polymyxin B for injection DI Handley

Research Based Presentation on- Novel Hydrogel-Based Ocular Drug Delivery Sy...
Research Based Presentation on- Novel Hydrogel-Based Ocular Drug Delivery  Sy...Research Based Presentation on- Novel Hydrogel-Based Ocular Drug Delivery  Sy...
Research Based Presentation on- Novel Hydrogel-Based Ocular Drug Delivery Sy...
Manusinghai2
 
Bioassay 112070804012
Bioassay 112070804012Bioassay 112070804012
Bioassay 112070804012
Patel Parth
 

Similar to Polymyxin B for injection DI Handley (20)

Solubility Enhancement, Stability and Scalability of Mesoporous Silica Formul...
Solubility Enhancement, Stability and Scalability of Mesoporous Silica Formul...Solubility Enhancement, Stability and Scalability of Mesoporous Silica Formul...
Solubility Enhancement, Stability and Scalability of Mesoporous Silica Formul...
 
microbial assay antibiotics, vitamins, amino acids
microbial assay antibiotics,  vitamins,  amino acidsmicrobial assay antibiotics,  vitamins,  amino acids
microbial assay antibiotics, vitamins, amino acids
 
Microbiological assays- Pharmacuetical Microbiology
Microbiological assays- Pharmacuetical MicrobiologyMicrobiological assays- Pharmacuetical Microbiology
Microbiological assays- Pharmacuetical Microbiology
 
Quality control of semisolids
Quality control of semisolidsQuality control of semisolids
Quality control of semisolids
 
Effectiveness of Sodium Citrate as a buffering agent for flucloxacillin infus...
Effectiveness of Sodium Citrate as a buffering agent for flucloxacillin infus...Effectiveness of Sodium Citrate as a buffering agent for flucloxacillin infus...
Effectiveness of Sodium Citrate as a buffering agent for flucloxacillin infus...
 
Micro assay dr. saisivam (04-03-2016)
Micro assay   dr. saisivam (04-03-2016)Micro assay   dr. saisivam (04-03-2016)
Micro assay dr. saisivam (04-03-2016)
 
2-5_StabilityPrinciples_CaseStudies.ppt
2-5_StabilityPrinciples_CaseStudies.ppt2-5_StabilityPrinciples_CaseStudies.ppt
2-5_StabilityPrinciples_CaseStudies.ppt
 
Research Based Presentation on- Novel Hydrogel-Based Ocular Drug Delivery Sy...
Research Based Presentation on- Novel Hydrogel-Based Ocular Drug Delivery  Sy...Research Based Presentation on- Novel Hydrogel-Based Ocular Drug Delivery  Sy...
Research Based Presentation on- Novel Hydrogel-Based Ocular Drug Delivery Sy...
 
processing and manufacturing of small volume parental
processing and manufacturing of small volume parentalprocessing and manufacturing of small volume parental
processing and manufacturing of small volume parental
 
Stability study for formulation
Stability study for formulation Stability study for formulation
Stability study for formulation
 
Bioassay 112070804012
Bioassay 112070804012Bioassay 112070804012
Bioassay 112070804012
 
Developing specifications q3 q6
Developing specifications  q3 q6Developing specifications  q3 q6
Developing specifications q3 q6
 
Microbial Assay of Antibiotics
Microbial Assay of AntibioticsMicrobial Assay of Antibiotics
Microbial Assay of Antibiotics
 
Pharmaceuticals protein
Pharmaceuticals proteinPharmaceuticals protein
Pharmaceuticals protein
 
Aseptic-Processing-of-Biological-Products--Current-Regulatory-Issues--Candace...
Aseptic-Processing-of-Biological-Products--Current-Regulatory-Issues--Candace...Aseptic-Processing-of-Biological-Products--Current-Regulatory-Issues--Candace...
Aseptic-Processing-of-Biological-Products--Current-Regulatory-Issues--Candace...
 
Vita microbial assay
Vita microbial assayVita microbial assay
Vita microbial assay
 
chemical character OF DRUG.pptx
chemical character OF DRUG.pptxchemical character OF DRUG.pptx
chemical character OF DRUG.pptx
 
Miscellaneous test .pdf
Miscellaneous test .pdfMiscellaneous test .pdf
Miscellaneous test .pdf
 
Preformulation studies part 2 mz
Preformulation studies part 2 mzPreformulation studies part 2 mz
Preformulation studies part 2 mz
 
Stability study
Stability studyStability study
Stability study
 

More from Megan Handley

final poster handley 3
final poster handley 3final poster handley 3
final poster handley 3
Megan Handley
 
Poster Presentation FINAL Draft
Poster Presentation FINAL DraftPoster Presentation FINAL Draft
Poster Presentation FINAL Draft
Megan Handley
 
Journal Club PCC Megan Handley
Journal Club PCC Megan HandleyJournal Club PCC Megan Handley
Journal Club PCC Megan Handley
Megan Handley
 
Menopause Presentation
Menopause PresentationMenopause Presentation
Menopause Presentation
Megan Handley
 
DI protein C and S deficiency TSOACs
DI protein C and S deficiency TSOACsDI protein C and S deficiency TSOACs
DI protein C and S deficiency TSOACs
Megan Handley
 
Vancomycin Journal Club
Vancomycin Journal ClubVancomycin Journal Club
Vancomycin Journal Club
Megan Handley
 
Role of latex allergies in vaccination- HANDOUT
Role of latex allergies in vaccination- HANDOUTRole of latex allergies in vaccination- HANDOUT
Role of latex allergies in vaccination- HANDOUT
Megan Handley
 

More from Megan Handley (7)

final poster handley 3
final poster handley 3final poster handley 3
final poster handley 3
 
Poster Presentation FINAL Draft
Poster Presentation FINAL DraftPoster Presentation FINAL Draft
Poster Presentation FINAL Draft
 
Journal Club PCC Megan Handley
Journal Club PCC Megan HandleyJournal Club PCC Megan Handley
Journal Club PCC Megan Handley
 
Menopause Presentation
Menopause PresentationMenopause Presentation
Menopause Presentation
 
DI protein C and S deficiency TSOACs
DI protein C and S deficiency TSOACsDI protein C and S deficiency TSOACs
DI protein C and S deficiency TSOACs
 
Vancomycin Journal Club
Vancomycin Journal ClubVancomycin Journal Club
Vancomycin Journal Club
 
Role of latex allergies in vaccination- HANDOUT
Role of latex allergies in vaccination- HANDOUTRole of latex allergies in vaccination- HANDOUT
Role of latex allergies in vaccination- HANDOUT
 

Polymyxin B for injection DI Handley

  • 1. Megan Handley PharmD Candidate Class of 2015 Drug Information Question Polymyxin B sulfate stability and compatibility with bacitracin for injection Polymyxin B for injection Package Insert (Sagent)  “Polymyxin B sulfate solutions for parenteral use should be stored under refrigeration and any unused portion should be discarded within 72 hours.”  Dosage and Administration o Parenteral:  Dissolve 500,000 polymyxin B units in 300-500 mL of 5% Dextrose Injection for continuous intravenous drip o Intramuscular:  Dissolve 500,000 polymyxin B units in 2 mL sterile water for injection or 0.9% sodium chloride or procaine hydrochloride injection 1% o Intrathecal  Dissolve 500,000 polymyxin B units in 10 mL 0.9% sodiumchloride injection for 50,000 units per mL dosage  Storage Recommendations o After reconstitution, product must be stored under refrigeration, between 2º and 8ºC (36º and 46º F) and any unused portion should be discarded after 72 hours. Stability of polymyxin B sulfate diluted in 0.9% sodium chloride injection and stored at 4 or 25º C (He et al.)  The study analyzed the stability of polymyxin B in infusion bags containing 0.9% sodium chloride at room temperature and underrefrigeration  They found that on average, the samples retained over 90% of their initial concentration for up to two days at both storage temperatures.  All samples retained over 90% of their initial concentration at 24 hours  The decomposition kinetics of polymyxin B in infusion bags containing 0.9% sodium chloride injection exhibited pseudo-first-order kinetics o Rate constants of0.024-0.075 day-1 at 25ºC (loss of 2.4-7.5% concentration daily) o Rate constants of0.022-0.043 day-1 at 4ºC (loss of 2.2-4.3% concentration daily)  Polymyxin B was stable for at least 1 day when stored at 4 or 25ºC in infusion bags containing 0.9% sodium chloride injection. o Stability did not significantly differ between the two temperatures.  Table 1 and Table 2 (attached) in the study break down the various manufacturers and lot numbers and report the percentage of the original concentration of polymyxin b sulfate that remains each day. Results are reported for both 4 and 25ºC.  Based upon this study, I would keep all reconstituted polymyxinB in the refrigerator to lengthen its stability.I also would discard the reconstituted product 48 hours after reconstitution. It would also be good practice to make sure all employees note the day and exact time the product was reconstituted so it can be discarded appropriately. MICROMEDEX IV Compatibility Analysis  Solutions reported to be compatible with polymyxin B include Dextrose 5%, Normal Saline (sodium chloride 0.9%), and invert sugar7.5% with electrolytes.
  • 2.  The compatibility detail for polymyxin B sulfate (0.0564-0.078 mg/mL) and normal saline (sodium chloride 0.9%), cited the He et al. as their source for the reported stability of polymyxin B in sodium chloride solution.  The information specifies: All samples retained over 90% of their original concentration at 24 hours. Within 48 hours,the concentrations in some samples exhibited greater than 10% loss in concentration,with one sample having 17% lost.  Bacitracin is not on the Micromedex list of compatible medications for IV treatment with polymyxin B. Dactinomycin, daptomycin, octreotide, and cyclosporine are alternative cyclic peptides that are compatible with polymyxin B sulfate for intravenous therapy. Summary Overall, there is very limited research thus far regarding the stability of polymyxin B sulfate in normal saline solution. The package insert mentioned above does mention that polymyxin B can be reconstituted with normal saline; however the storage recommendations do not specify a certain time period for each diluent. They simply apply a 72 hourlimit on all reconstituted solutions ofpolymyxin B, which is the known time for polymyxin B to lose stability in 5% dextrose. He et al. conducted a study determining how much time must elapse for a solution of polymyxin B sulfate in sodiumchloride injection to reach a concentration of less than 90% of its original strength.Since this study was specific to normal saline as a diluent, the results may in turn be more specific than those mentioned in the package insert. They determined polymyxin B sulfate was stable after reconstitution for at least 1 day when stored at either 4 or 25ºC (stability being defined as greater than 90% of the original concentration of polymyxin B.) Most solutions maintained greater than 90% of their concentration after 48 hours,with the exception of some samples. More samples of polymyxin B in normal saline bags maintained a stable concentration after 48 days if they were refrigerated; however, the difference between the two groups was not statistically significant.